Light therapy effects on cell energy in healthy people and type 1 diabetes
Tests red and near-infrared light on blood cell energy in people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: The Effect of Light Therapy on Cellular Energy and Oxidative Stress in Healthy Adults and Type 1 Diabetic Patients
Key facts
- Where
- Nasiriyah, IraqSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 40 years old?
Source: NCT07833865, who can take part
Where in Iraq
- Al Nasiriya Teaching HospitalNasiriyah, IraqNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Thi-Qar
- Trial code
- NCT07833865
- Record updated
- 16 October 2026
- Original description
The goal of this clinical trial is to evaluate the effects of low-level light therapy on cellular energy and oxidative stress in healthy adults and patients with Type 1 diabetes. The main questions it aims to answer are:Read full original descriptionShow less
Biochemical Study of Metabolic Regulation and Extraction of Mitochondrial Biomarkers in Type 1 Diabetes Mellitus in Thi-Qar Governorate, Iraq
The goal of this clinical trial is to evaluate the effects of low-level light therapy on cellular energy and oxidative stress in healthy adults and patients with Type 1 diabetes. The main questions it aims to answer are:
Does light therapy change adenosine triphosphate (ATP) levels and cytochrome c oxidase activity in blood cells? How does the intervention affect oxidative stress markers, specifically glutathione and malondialdehyde concentrations? Researchers will compare blood samples collected before the light therapy to those collected afterward to see if the intervention alters mitochondrial function. Researchers will also compare the responses of healthy volunteers to those of diabetic patients.
Participants will:
Provide a baseline blood sample. Receive red and near-infrared light exposure (660 nm and 850 nm) on their arms for 10 to 20 minutes using a therapy pad.
Provide a final blood sample immediately after the light exposure.
Inclusion: Age 12 to 40 years; Confirmed diagnosis of Type 1 Diabetes Mellitus based on American Diabetes Association criteria (patient group); Insulin dependence (patient group); Low serum C-peptide levels (patient group); Fasting plasma glucose concentration <100 mg/dL (healthy control group); Glycated haemoglobin (HbA1c) <5.7% (healthy control group); Diabetes duration of at least 1 year (patient group).
Exclusion: High-sensitivity C-reactive protein (hs-CRP) >10 mg/L or active infection; Renal insufficiency; Liver disease; Autoimmune diseases other than Type 1 Diabetes Mellitus; Haematological disorders; Diabetic ketoacidosis within the preceding month; Pregnancy; Smoking; Use of antioxidant supplements, vitamin C, or vitamin E within the preceding month.